Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224516 · ClinicalTrials.gov registry record · NA
Testing MOUD Scale-Up
A NA study of Incarcerated Individuals and Correctional Institutions, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07224516: Recruiting NA study of Incarcerated Individuals and Correctional Institutions, sponsored by University of Wisconsin, Madison.
NCT07224516 is a NA study of Incarcerated Individuals and Correctional Institutions that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224516, a NA study of Incarcerated Individuals and Correctional Institutions, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to improve health outcomes for incarcerated individuals by increasing medications for opioid use disorder (MOUD) use, using scalable and cost-effective methods that could be applied more broadly in the criminal justice system.
Primary Outcome
Using the RE-AIM framework, reach is measured by number of MOUD (buprenorphine, methadone, injectable naltrexone) standardized medication units purchased by prisons in a state
Conditions Studied
Interventions
- BEHAVIORAL Learning Collaborative
- BEHAVIORAL SAMHSA
Study Locations (1)
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-02-05 |
| Est. Completion | 2028-08 |
| Phase | NA |
What NCT07224516 shows while recruiting
NCT07224516 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Incarcerated Individuals appearing as the primary indexed condition, and to 2 interventions - of which Learning Collaborative is the first listed.
NCT07224516 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07224516 about?
NCT07224516 is a clinical study titled "Testing MOUD Scale-Up". The goal of this clinical trial is to improve health outcomes for incarcerated individuals by increasing medications for opioid use disorder (MOUD) use, using scalable and cost-effective methods that could be applied more broadly in the criminal justice system.
What is the current status of trial NCT07224516?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2026-02-05. Estimated completion is 2028-08.
What conditions does trial NCT07224516 study?
This clinical trial studies the following conditions: Incarcerated Individuals, Correctional Institutions.
What interventions are being tested in trial NCT07224516?
The interventions under investigation include: Learning Collaborative (BEHAVIORAL), SAMHSA (BEHAVIORAL).
Who is sponsoring clinical trial NCT07224516?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224516 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07224516's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI